PeptiMed, Inc.
PeptiMed, Inc. is a Madison, Wisconsin-based biotechnology company that develops therapeutic drugs targeting the EVI1 gene for the treatment of skin, breast, lung, prostate, and ovarian cancers.
All edits
PeptiMed, Inc.
PeptiMed, Inc. is a Madison, Wisconsin-based company founded in 2012 by Scott Schneider.
PeptiMed, Inc. is a Madison, Wisconsin-based biotechnology company that develops therapeutic drugs targeting the EVI1 gene for the treatment of skin, breast, lung, prostate, and ovarian cancers.
PeptiMed, Inc. is a Wisconsin-based company founded in 2012 by Scott Schneider. It operates as a biotechnology company that develops therapeutic drugs targeting the EVI1 gene for the treatment of skin, breast, lung, prostate, and ovarian cancers.
PeptiMed, Inc.
PeptiMed, Inc. is a Madison, Wisconsin-based biotechnology company that develops therapeutic drugs targeting the EVI1 gene for the treatment of skin, breast, lung, prostate, and ovarian cancers.
PeptiMed, Inc.
PeptiMed, Inc. is a Madison, Wisconsin-based company founded in 2012 by Scott Schneider. It operates as a biotechnology company that develops therapeutic drugs targeting the EVI1 gene for the treatment of skin, breast, lung, prostate and ovarian cancers.
PeptiMed, Inc. is a Wisconsin-based company founded in 2012 by Scott Schneider. It operates as a biotechnology company that develops therapeutic drugs targeting the EVI1 gene for the treatment of skin, breast, lung, prostate and ovarian cancers.
PeptiMed, Inc.
PeptiMed, Inc. is a Madison, Wisconsin-based company founded in 2012 by Scott Schneider. It operates as a biotechnology company that develops therapeutic drugs targeting the EVI1 gene for the treatment of skin, breast, lung, prostate and ovarian cancers.
Find more companies like PeptiMed, Inc.
